Chief Business Officer · Avalo Therapeutics, Inc. (AVTX)

Taylor Boyd

FY2025 is the first fiscal year CompBrief holds for Taylor Boyd as a named executive officer of Avalo Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,219,751

2nd of 4 named executive officers at Avalo Therapeutics by FY2025 total.

4 named officers on file for Avalo Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Avalo Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2026 (DEF 14A).

Free

Get Taylor Boyd’s full pay file as a PDF — free

More than this page: up to 10 years of Taylor’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Taylor Boyd and every company like it: Velarion Intel, free for 3 days, no card →

Taylor Boyd compensation by year

Avalo Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$116,250
Bonus$0
Stock awards$0
Option awards$3,049,481
Non-equity incentive$52,080
Pension and deferred compensation$0
All other$1,940
Total$3,219,751

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed April 10, 2026, accession 0001534120-26-000022, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001534120-26-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option275,000—$12.96

Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Avalo Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Garry NeilChief Executive Officer, President and principal executive officer$3,807,581
Taylor Boyd · this pageChief Business Officer$3,219,751
Mittie FACRChief Medical Officer$1,780,557
Mittie DoyleChief Medical Officer$1,780,557

Taylor Boyd's compensation dossier, Avalo Therapeutics

You have read Taylor Boyd's totals and holdings. The dossier adds each equity grant Avalo Therapeutics disclosed for Taylor Boyd and Avalo Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Avalo Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order AVTX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Taylor Boyd's compensation dossier